Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2021-11-02 Governance Information
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Constitution as amended 3 November 49 pages 356.3KB
Governance Information Classification · 95% confidence The document is titled 'Pharmaxis Ltd Constitution' and contains detailed provisions about the company's shares, share capital, calls, liens, and other governance-related rules. It is a legal and governance document outlining the internal rules and structure of the company rather than a financial report, announcement, or meeting material. There is no indication of financial data, earnings, voting results, or management changes. The content aligns with governance practices and company constitution details. Therefore, the document best fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full constitution text, not a brief announcement or summary.
2021-11-02 English
Notification regarding unquoted securities - PXS 6 pages 28.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted securities under an employee incentive scheme by Pharmaxis Ltd. It includes specifics such as the number of securities issued, dates, and mentions key management personnel involved. The content focuses on the issuance of securities and related compliance with ASX listing rules. There is no financial performance data, earnings information, or management discussion. The document is an announcement regarding a capital change, specifically the issuance of new securities. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is over 5,000 characters and contains substantive details about the securities issued, not just a brief notice or link to a report, so it is not a Report Publication Announcement or Regulatory Filing.
2021-11-02 English
Change of Director's Interest Notice 2 pages 144.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares and options held before and after the change, nature of the change, and dates. This matches the description of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives (insider trades). The document is not an announcement of a report, nor a full financial report, but a specific regulatory filing about director share transactions.
2021-11-02 English
Appendix 4C Cash Flow Report 4 pages 199.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements including operating, investing, and financing activities. It includes specific quarterly financial data, reconciliations, and compliance statements. The presence of detailed financial data for a quarter and the format consistent with a quarterly cash flow report indicates this is a comprehensive interim financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2021-10-27 English
Quarterly Activities Report 12 pages 517.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – September 2021' and contains detailed information about clinical trial progress, drug development pipeline, impact of COVID-19 on operations, and business outlook. It includes substantive data on clinical trial phases, drug statuses, and company activities within the quarter. The length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content is consistent with a quarterly report providing financial and operational updates for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2021
2021-10-27 English
Investor Presentation - September Quarterly Update 9 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation | 28 October 2021 Gary Phillips CEO' and contains detailed information about Pharmaxis' clinical programs, drug development pipeline, clinical trial progress, financial position, capital structure, and anticipated news flow. It includes forward-looking statements, executive summary, clinical trial data, cash and capital structure details, and future milestones. The content is typical of an investor presentation aimed at providing investors with a comprehensive overview of the company's strategy, clinical progress, and financial outlook. There is no indication that this is a regulatory filing, earnings release, or annual/interim report. The length (11,404 characters) and detailed content support classification as an investor presentation rather than a brief announcement or report publication notice.
2021-10-27 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.